Cargando…
Breast cancer risk-assessment models
There are two main questions when assessing a woman for interventions to reduce her risks of developing or dying from breast cancer, the answers of which will determine her access: What are her chances of carrying a mutation in a high-risk gene such as BRCA1 or BRCA2? What are her risks of developin...
Autores principales: | , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2242652/ https://www.ncbi.nlm.nih.gov/pubmed/17888188 http://dx.doi.org/10.1186/bcr1750 |
_version_ | 1782150560556777472 |
---|---|
author | Evans, D Gareth R Howell, Anthony |
author_facet | Evans, D Gareth R Howell, Anthony |
author_sort | Evans, D Gareth R |
collection | PubMed |
description | There are two main questions when assessing a woman for interventions to reduce her risks of developing or dying from breast cancer, the answers of which will determine her access: What are her chances of carrying a mutation in a high-risk gene such as BRCA1 or BRCA2? What are her risks of developing breast cancer with or without such a mutation? These risks taken together with the risks and benefits of the intervention will then determine whether an intervention is appropriate. A number of models have been developed for assessing these risks with varying degrees of validation. With further improvements in our knowledge of how to integrate risk factors and to eventually integrate further genetic variants into these models, we are confident we will be able to discriminate with far greater accuracy which women are most likely to develop breast cancer. |
format | Text |
id | pubmed-2242652 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2007 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-22426522008-02-14 Breast cancer risk-assessment models Evans, D Gareth R Howell, Anthony Breast Cancer Res Review There are two main questions when assessing a woman for interventions to reduce her risks of developing or dying from breast cancer, the answers of which will determine her access: What are her chances of carrying a mutation in a high-risk gene such as BRCA1 or BRCA2? What are her risks of developing breast cancer with or without such a mutation? These risks taken together with the risks and benefits of the intervention will then determine whether an intervention is appropriate. A number of models have been developed for assessing these risks with varying degrees of validation. With further improvements in our knowledge of how to integrate risk factors and to eventually integrate further genetic variants into these models, we are confident we will be able to discriminate with far greater accuracy which women are most likely to develop breast cancer. BioMed Central 2007 2007-09-12 /pmc/articles/PMC2242652/ /pubmed/17888188 http://dx.doi.org/10.1186/bcr1750 Text en Copyright © 2007 BioMed Central Ltd |
spellingShingle | Review Evans, D Gareth R Howell, Anthony Breast cancer risk-assessment models |
title | Breast cancer risk-assessment models |
title_full | Breast cancer risk-assessment models |
title_fullStr | Breast cancer risk-assessment models |
title_full_unstemmed | Breast cancer risk-assessment models |
title_short | Breast cancer risk-assessment models |
title_sort | breast cancer risk-assessment models |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2242652/ https://www.ncbi.nlm.nih.gov/pubmed/17888188 http://dx.doi.org/10.1186/bcr1750 |
work_keys_str_mv | AT evansdgarethr breastcancerriskassessmentmodels AT howellanthony breastcancerriskassessmentmodels |